This suit was surfaced by Law.com Radar, ALM's source for immediate alerting on just filed cases in state and federal courts.

The Bausch + Lomb IPO established two separate companies that include — a diversified pharmaceutical company (comprised of the Salix, International, Diversified [neurology, dermatology, generic and ...

Federal Reserve's rate cut boosted tech, construction, industrial, machinery, and financial sectors. Top-performing mid-cap ...

Hedge fund managers sit on the boards of Bausch Health and Bausch + Lomb. They don’t think like your typical corporate board, ...

Bausch + Lomb has a pretty solid balance sheet that hasn’t changed a lot in the last few quarters. Read why I remain bullish ...

Bausch + Lomb is assessing interest from potential buyers as a way around the roadblock, the FT wrote. The company had a market cap of $6.27 billion on Monday.

Larry Biegelsen, an analyst from Wells Fargo, assigned the Buy rating on Bausch + Lomb Corporation (BLCO – Research Report). The ...

Analyst Larry Biegelsen from Wells Fargo maintained a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report) and keeping the ...

Bausch + Lomb BLCO shares ended the last trading session 14.5% higher at $17.80. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This ...

Share moves to note in North America include Bausch & Lomb, Apple and Trump Media & Technology Group: Shares of eyecare company Bausch & Lomb surged 13.7 per cent on Monday, after the FT on the ...